Page last updated: 2024-12-08
fc 80
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
perfluorobutyl tetrahydrofuran: was MH 1975-92 (see under FLUOROCARBONS 1978-90, see under FURANS 1975-77); FC-80 & PERFLUOROCHEMICAL FC-80 were see PERFLUOROBUTYL TETRAHYDROFURAN 1978-92; use FLUOROCARBONS to search PERFLUOROBUTYL TETRAHYDROFURAN 1978-92 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 134921 |
| CHEBI ID | 39029 |
| SCHEMBL ID | 104183 |
| MeSH ID | M0197600 |
Synonyms (20)
| Synonym |
|---|
| furan, tetrahydro(nonafluorobutyl)- |
| fx-80 |
| (perfluorobutyl)tetrahydrofuran |
| perfluorobutyl tetrahydrofuran |
| perfluorochemical fc-80 |
| fc-80 |
| 26446-59-3 |
| 2-(nonafluorobutyl)tetrahydrofuran |
| CHEBI:39029 |
| fx 80 |
| 2-perfluorobutyltetrahydrofuran |
| perfluorobutyltetrahydrofuran |
| 2-(1,1,2,2,3,3,4,4,4-nonafluorobutyl)oxolane |
| 25962-44-1 |
| SCHEMBL104183 |
| DTXSID90276353 |
| (nonafluorobutyl)tetra hydrofuran |
| Q27118100 |
| cjfuepjvifjoou-uhfffaoysa-n |
| tetrahydro(perfluorobutyl)furan |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although PFC evaporation from the lungs is in part dependent on ventilation strategy and positioning, guidelines for initial and replacement dosing are unclear." | ( Perfluorochemical elimination from the lungs: effect of initial dose. Fox, WW; Philips, CM; Shaffer, TH; Weis, CM; Wolfson, MR, 2000) | 0.31 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
| Class | Description |
|---|---|
| organofluorine compound | An organofluorine compound is a compound containing at least one carbon-fluorine bond. |
| alkyltetrahydrofuran | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 35.65
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (35.65) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (8.33%) | 5.53% |
| Reviews | 1 (8.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||